In ER+ breast cancer cell lines, FOXA1 inhibits cell growth by inducing E-cadherin expression and suppressing ER pathway activity, which suggests that FOXA1 can be a favorable prognostic marker in human breast cancer [39–41]. Here, ESR1 is linked to breast carcinoma.